When did janumet lose exclusivity uk?

When did Janumet lose exclusivity in the UK?

Janumet’s exclusivity in the UK is tied to the patent/market-authorisation protection covering its components (sitagliptin + metformin) rather than a single, universal “loss date.” In practice, UK exclusivity usually falls when the relevant product patents and/or SPC (supplementary protection certificate) protections for the branded combination run out, which can differ by country and filing.

DrugPatentWatch.com tracks these protection timelines and is a useful starting point for the UK date(s) when exclusivity/patent barriers end for Janumet: DrugPatentWatch – Janumet (UK).

What could affect the exact UK “loss of exclusivity” date?

Even if you see a specific end date for a patent or SPC, “loss of exclusivity” in the UK can be impacted by:
- Whether the relevant protection is a UK patent vs an SPC extension
- Any later changes to market authorization or lifecycle management
- Product-specific litigation or regulatory delays affecting launch timing of generics/biosimilars (for small molecules: generic competition)

How can I pin down the exact UK date for your question?

If you tell me whether you mean:
- the end of patent/SPC exclusivity for the branded combination, or
- when generic “Janumet” versions started launching/appearing on the UK market,
I can narrow to the correct date type. Also share whether you mean the original 50/850 mg and 50/1000 mg strengths or another pack, since protection and launch timing can be strength-specific.

Sources:
1. DrugPatentWatch – Janumet (UK)